Cardiovascular secondary prevention

  • 文章类型: Journal Article
    背景:目前的指南建议在接受过治疗的患者经皮冠状动脉介入治疗(PCI)后逐步开始降脂治疗。通过前期联合治疗,患者可能会从更早和更强的低密度脂蛋白胆固醇(LDL-C)降低中受益。
    方法:这项回顾性研究包括2016年1月至2019年12月期间未接受过降脂治疗的急性或择期PCI支架植入术患者。开始使用他汀类药物单一疗法的患者与比较了他汀类药物和依泽替米贝的组合.主要终点是在3个月时LDL-C降低至<55mg/dL的目标范围。次要终点是主要心血管事件(MACE)的发生。
    结果:共纳入204例未接受降脂治疗的患者,其中157人(77.0%)接受他汀单药治疗,47人(23.0%)接受联合治疗.接受联合治疗的患者的LDL-C中位数较高,而接受联合治疗的患者单一疗法(140mg/dL,四分位数间距,IQR,123-167mg/dLvs.102mg/dL,IQR80-136mg/dL,p<0.001)。与接受联合治疗的患者相比,LDL-C降低更大他汀类药物单一疗法(-73mg/dL,-52.1%vs.-43mg/dL,-42.2%,p<0.001)。而两组的主要终点相似(44.7%vs.36.1%,p=0.275),联合治疗显着增加了在存在入院LDL-C>120mg/dL的情况下达到治疗目标的患者比例(46.2%vs.26.2%,p=0.031)。两组的MACE发生率相似(10.6%vs.17.8%,p=0.237),中位随访时间为2.2年,IQR1.46-3.10年。
    结论:立即开始高强度他汀类药物和依泽替米贝治疗可能被认为是接受PCI的高LDL-C患者的默认治疗策略。
    BACKGROUND: Current guidelines recommend a stepwise initiation of lipid-lowering therapy after percutaneous coronary interventions (PCI) in treatment-naïve individuals. Patients might benefit from an earlier and stronger low-density lipoprotein-cholesterol (LDL-C) reduction through upfront combination therapies.
    METHODS: This retrospective study included patients without previous lipid-lowering therapy undergoing acute or elective PCI with stent implantation between January 2016 and December 2019. Patients initiated on statin monotherapy vs. a combination of statin and ezetimibe were compared. The primary endpoint was an LDL‑C reduction into the target range of < 55 mg/dL at 3 months. The secondary endpoint was the occurrence of major cardiovascular events (MACE).
    RESULTS: A total of 204 lipid-lowering therapy naive patients were included, of whom 157 (77.0%) received statin monotherapy and 47 (23.0%) combination therapy. Median LDL‑C levels were higher in patients initiated on combination therapy vs. monotherapy (140 mg/dL, interquartile range, IQR, 123-167 mg/dL vs. 102 mg/dL, IQR 80-136 mg/dL, p < 0.001). The LDL‑C reduction was greater in patients treated with combination therapy vs. statin monotherapy (-73 mg/dL, -52.1% vs. -43 mg/dL, -42.2%, p < 0.001). While the primary endpoint was similar between groups (44.7% vs. 36.1%, p = 0.275), combination therapy significantly increased the proportion of patients achieving the treatment target in the presence of an admission LDL-C > 120 mg/dL (46.2% vs. 26.2%, p = 0.031). The rates of MACE were similar between the two groups (10.6% vs. 17.8%, p = 0.237) at a median follow-up of 2.2 years, IQR 1.46-3.10 years.
    CONCLUSIONS: Immediate initiation of high-intensity statin and ezetimibe treatment might be considered as the default strategy in treatment-naïve patients with high admission LDL‑C undergoing PCI.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:尽管人们对心血管患者的药物依从性了解很多,临床医生认为非依从性在临床实践中是一个障碍的程度还很少被探讨.目的评估对药物依从性潜在障碍的知识和认识,并评估葡萄牙临床医生在临床实践中使用的策略,以提高接受二级心血管预防的患者的药物依从性。在里斯本大学设置名义组技术(NGT);在线调查针对在葡萄牙的初级和二级保健工作的医生。方法在Pubmed中进行了叙述性文献综述,以确定描述针对医生管理药物依从性的干预措施的研究。NGT包括12名在药物依从性方面具有公认专业知识的专职医疗专业人员,并分四个阶段进行组织。导致调查发展。这项调查被用于一项全国横断面研究,临床医生报告了他们对患者服药依从性和日常实践的知识和看法。主要结果指标对药物依从性障碍的知识和认识;和实践模式。结果共鉴定出296篇论文,其中包括26个。在NGT中选择了四个主要主题:依从性决定因素,检测不依从性,促进坚持,和教育医生。NGT导致了一项调查,达到451名医生,主要是在初级保健中执业。大多数人对药物依从性进行了专门的教育,并认为患者访谈和处方记录是最有用的评估方法。尽管如此,许多人认识到经常使用临床判断来评估实践中的依从性。在实施过程中,人们认为药物依从性的障碍经常发生。不受控制的高血压的大多数感知原因是不遵守生活方式建议和药物治疗。不到一半的医生询问患者是否服用药物。更有用的启用策略包括减少每日剂量,回顾治疗方案和动机干预措施。结论临床医生似乎很了解药物依从性的重要性,并意识到实践中遇到的问题。医疗预约期间的有限时间可能是更好的患者支持的障碍。
    BACKGROUND: Although much is known about cardiovascular patients\' medication adherence, the extent to which clinicians perceive non-adherence as a barrier in clinical practice is little explored. Objective To evaluate knowledge and awareness about potential barriers to medication adherence, and to evaluate strategies used in clinical practice by Portuguese clinicians on how to foster medication adherence of patients undergoing secondary cardiovascular prevention. Setting Nominal Group Technique (NGT) at the University of Lisbon; online survey addressed to physicians working in primary and secondary care in Portugal. Method A narrative literature review was conducted in Pubmed to identify studies describing interventions targeted at physicians to manage medication adherence. The NGT included 12 allied healthcare professionals with recognized expertise in medication adherence and was organised in four phases, resulting in survey development. The survey was used in a cross-sectional national study where clinicians reported their knowledge and perceptions about patients\' medication adherence and their daily practice. Main outcome measures Knowledge and awareness about barriers to medication adherence; and practice patterns. Results A total of 296 papers were identified, 26 of which were included. Four main topics were selected to be used in the NGT: adherence determinants, detecting non-adherence, fostering adherence, and educating physicians. NGT resulted in a survey, reaching 451 physicians, mostly practicing in primary care. Most had specific education on medication adherence and considered patient interviews and prescription records the most useful assessment methods. Nonetheless, many recognised often using clinical judgement to evaluate adherence in practice. Barriers to medication adherence were perceived to occur often during implementation. Most perceived reasons for uncontrolled hypertension were non-adherence to lifestyle recommendations and to medication. Less than half the physicians asked their patients if medication was taken. More useful enabling strategies included reducing daily doses, reviewing therapeutic options and motivational interventions. Conclusions Clinicians seem well informed about the importance of medication adherence and aware of problems encountered in practice. Limited time during medical appointment may be a barrier for better patient support.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号